An interventional study of Virtual Reality Distraction and Standard Treatment in Atopic Dermatitis, Pain and Anxiety, sponsored by St. Justine's Hospital. Recruiting at 2 sites in Canada. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by St. Justine's Hospital · Not applicable, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Dermatitis, Atopic with a site in Canada — 18 open to participants now, 44 under way, 13 of them phase 3. Dermatitis, Atopic · Canada.
Among the 225 studies in Dermatitis, Atopic with a site in Canada, this one is the 148th largest by planned enrollment of the 207 interventional ones that give a count, is one of 13 that started in 2024, is one of 9 with no phase, reaches primary completion later than 16 of the 43 other live ones, and was the 176th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →18 of the 225 studies in Dermatitis, Atopic with a site in Canada are open now. Recruiting first, the newest first:
Triveni Bio · Sites in Canada, United States, Ukraine
Ages 18–75
Pfizer · Sites in Canada, United States, Japan and 1 more country
Ages 12+
Pfizer · Sites in Canada, United States, Japan
Ages 12+
Apollo Therapeutics Ltd · Sites in Canada, United States, Bulgaria and 5 more countries
Ages 18–65
Pfizer · Sites in Canada, United States, Bulgaria and 6 more countries
Ages 18–64
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 108 · Phase 3 70 · Phase 4 8
First in 2002; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 206 across the 207 interventional studies, 305 across the 17 observational. Of the 178 that completed or were terminated, 120 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
206 of 225 have an industry lead sponsor. The 10 most frequent:
St. Justine's Hospital is the lead sponsor of 156 studies on the registry; 27 are open to participants now.
St. Justine's Hospital has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
14 of the studies in Dermatitis, Atopic with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT06182436St. Justine's HospitalVirtual Reality for Pain Management During Dupilumab Injection | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 225 studies in Dermatitis, Atopic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this within-subject randomized study is to examine the efficacy of a VR immersive game for pain and anxiety management of children during the subcutaneous injection of dupilumab for moderate to severe atopic dermatitis. We will recruit children from 6 to 17 years.
The main research question is:
Participants will be randomized according to either sequences: VR-Standard care or Standard care-VR. During the VR sequence, participants will be playing the VR immersive game during the injection. During the Standard care sequence participants will not benefit from any pain management but passive distraction tools will be offered (and documented) to children.
The investigators will take measures of pain and anxiety, using validated scales, before and after the procedures at each sequence.
Background :
Atopic dermatitis is one of the most common inflammatory diseases of the skin and usually starts in early childhood.The prevalence of atopic dermatitis ranges from 15 to 20% among children and up to 10% in adults. Atopic dermatitis treatment has been revolutionized in the past years with the approval of dupilumab (Dupixent®, Sanofi) in recent years for children. Dupilumab subcutaneous injections are highly effective in our real-world setting. However, pain at the site of injection is often reported by the parents and the patients. Regardless of the site of injection or the injection device being used, the injection remains difficult mainly because of the anxiety generated before the procedure and the anticipated pain, even if the injection only lasts five seconds.
In addition, many strategies have been unsuccessfully attempted to improve the injection experience, for example numbing cream or anxiolytic administration prior to the injection. A few authors have studied the effect of Virtual Reality (VR) on procedural pain and anxiety management. Indeed, a review of the literature has yielded only three studies who used VR with burn children. One study has verified the efficacy of VR compared to standard pharmacological care in an RCT on 54 children (6 to 19 years) suffering from burn-related injuries with TBSA (Total Body Surface Area) varying from 1 to 50%. Results showed better pain control and maximum Range of Motion (ROM) of children in the VR group.
Finally, considering the lack of optimal pain and anxiety management during dupilumab subcutaneous injections for a subset of pediatric patients, and the positive effect of an immersive distraction method such as VR for painful procedures, using VR for dupilumab injections may show promising results. To our knowledge, no other studies have tested the effect of an immersive distraction such as VR for procedural pain and anxiety management in children suffering from atopic dermatitis receiving subcutaneous injections of dupilumab.
Aim of the study
The aim of this within-subject randomized clinical trial is to verify the efficacy of an immersive distraction (virtual reality) compared to the standard of care, for pain and anxiety management of children undergoing an injection of dupilumab for moderate to severe atopic dermatitis.
Hypothesis
The use of Virtual Reality (VR) as a distraction technique during dupilumab subcutaneous injections will provide better pain and anxiety management than the standard intervention alone.
Objectives
The primary objectives are as follows:
The secondary objectives are as follows:
Methods
Design
A within-subject randomized clinical trial design with randomized sequences. Given the difficulty of ensuring any blinding conditions with the nature of the experimentation, and in order to limit the interpersonal variability between participants, each child will serve as their own control, hence receiving both standard (control) and experimental treatments (VR) during two consecutive treatment visits through a randomized order.
Sample and setting
This study will consist of 98 patients with an attrition rate of 20% where each child will serve as their own control, hence receiving both standard (control) and experimental treatments during two consecutive treatment visits through a randomized order. Thus, making a total of 196 participants. Recruitment will be done through convenience sampling of patients in the dermatology department of CHU Ste-Justine, Montreal (Qc), Canada, receiving dupilumab for moderate to severe atopic dermatitis.
Study proceedings
Every participant will be randomized to either receive the control treatment or the experimental treatment in a successive order in two different visits. Each participant will receive the two treatments and act as their own control. For the control treatment, the research nurse will administrate the subcutaneous injection as prescribed without any distractive measure, as usually performed. For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection. The participant will not be aware that the purpose of the visit is to receive the subcutaneous dupilumab injection. The child will not be informed of the exact moment of the injection and will not receive notification prior to the injection to keep the maximal effect of the immersive distraction provided by the VR experience. On the next visit, the participant will receive the other treatment, in a randomized order.
Game specifications
The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. In the game, participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience. The game was made to minimize cybersickness and was approved by a team of healthcare professionals in pediatric care.
Study time-points and Secondary outcomes
Measures of pain with the Verbal Numerical Rating Scale (VNRS 0-10) and anxiety with the Child Fear Scale (CFS, 0-4) will be taken before the first treatment session at (T1), after the first treatment session (T2), before the second treatment session (T3), and after the second treatment session (T4). After T2 and T4, a measure of healthcare professionals' level of satisfaction via a questionnaire developed and pretested by the team will beadministered as well. Data will also be collected on the occurrence of side effects. Clinical monitoring will be performed by an independent nurse from the research team.
Measures of the primary outcomes
Pain intensity will be assessed using the Numerical Rating Scale (NRS) for children 6 years and older immediately after the procedure during each visit (T2 and T4). The NRS is an 11-item scale for pain intensity ranging from 0 to 10; 0=no pain to 10= worst pain ever felt. This scale has an established validity (Convergent validity with Faces Pain Scale-R: r = 0.75-0.93) and reliability (Test-retest using Bland-Altman agreement: -0.9 to 1.2, 95%CI) for self-reported pain intensity in children and adolescents (6 to 17 years old). Pain intensity will also be measured at T1 and T3 to establish baseline.
The level of anxiety will be assessed using the Child Fear Scale (CFS) immediately after the procedure at each visit (T2 and T4). The CFS is a self-reported measure of anxiety adapted from the adult Faces Anxiety Scale for specific use in children undergoing painful experiences. It consists of five faces ranging from 0 (no fear/anxiety) through 4 (extremely fearful/anxious). The child is asked to indicate which face shows best how he/she felt during the procedure. Test-retest reliability has been established with children aged 5 to 10 years during painful procedure (rs = 0.76) and concurrent validity with the Children Anxiety and Pain Scale (CAPS) (rs = 0.73). The CFS was chosen because of its psychometric qualities and it is a one-item self-measure of anxiety/fear. Moreover, "although fear tends to decrease with age in general, medical fears may be an exception". Also, "age-related differences in fear ratings have not been found". Further, this scale has been used with children ranging from 5 to 18 years old for procedural fear related to venipuncture and children from 11 to 13 years for fear/anxiety of vaccine.
Sample size and statistical analysis
Recruiting 98 patients being their own control will provide a total of 196 patients which is necessary to achieve 90% power to detect a mean of paired differences of 0,40 (medium effect) with an estimated standard deviation of differences of 1,00 and with a significance level (alpha) of 0,025 using a two-sided paired t-test considering a mean difference for pain of 2.0 with a standard deviation of 1.0, a mean difference for anxiety of 1.0 with a standard deviation of 1.0 and a significance level (alpha) of 0.05/2 for both components. This sample size considers an attrition rate of 20%. Comparisons will be conducted within and between subjects for the dependent variables for repeated measures. For all variables except adverse events, an analysis of variance with one within factor condition (distraction or standard care) and one between factor order will be used. The 95% confidence interval of the difference between treatment condition will be reported. All analysis will be done in intention-to-treat using a significance level of 0,05. For primary outcomes, the Bonferroni correction will be used for the multiplicity of tests. All adverse events will be described separately by treatment condition. Statistics will be performed by an independent biostatistician.
Discussion
The investigators believe that the results of this study will provide evidence-based knowledge on a non-pharmacological method for anxiety and pain management for patients with a chronic condition undergoing a long term recurrent painful and stressful treatment through innovative interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The child will play with the VR device for five minutes prior to the subcutaneous injection.
Device: Virtual Reality Distraction
Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention
Other: Standard Treatment
For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.
Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention. Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented
This study also gives DupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
mean difference in pain intensity score between sequences
Pain intensity will be assessed using the Numerical Rating Scale (NRS) for children 6 years and older. The NRS is an 11-item scale for pain intensity ranging from 0 to 10; 0=no pain to 10= worst pain ever felt.
Time frame: Immediately after the procedure on day 1 and a week later on day 2 (T2 and T4) (self-report of pain levels during the procedure).
mean difference in anxiety between sequences
The level of anxiety will be assessed using the Child Fear Scale (CFS). It consists of five faces ranging from 0 (no fear/anxiety) through 4 (extremely fearful/anxious). The child is asked to indicate which face shows best how he/she felt during the procedure.
Time frame: Immediately after the procedure on day 1 and a week later on day 2 (T2 and T4) (self-report of anxiety levels during the procedure).
Mean difference in cognitive, affective and sensory components of pain as well as sense of presence in VR and engagement into the game between groups
Assessed using the Graphic Rating Scale (GRS) a 7-item Likert-type scale tailored for virtual reality interventions.
Time frame: Reported immediately after the procedure on day 1 and a week later on day 2 (T2 and T4)
children's satisfaction levels
Assessed using a 0 to 10 numerical scale to answer the following question as recommended by PedIMMPACT (McGrath et al., 2008): "Considering pain relief, side effects, physical recovery, and emotional recovery, how satisfied were you with the treatments you/your child received for pain?"
Time frame: Reported immediately after the procedure on day 1 and a week later on day 2 (T2 and T4)
healthcare professionals' satisfaction levels
Healthcare professional's satisfaction level will be assessed using a tailored questionnaire with four choices response scale from Strongly agree to Strongly disagree for 7 items related to their level of satisfaction with the intervention and its effect on the procedure.
Time frame: Reported immediately after the sequence, a week later on day 2 (T4)
Occurrence of adverse events
Occurrence of adverse events will be assessed and documented from enrolment until discharge.
Time frame: Reported immediately after the procedure on day 1 and a week later on day 2 (T2 and T4)
parents' satisfaction levels
Parents's satisfaction levels will be assessed using a tailored questionnaire with four choices response scale from Strongly agree to Strongly disagree for 7 items related to their level of satisfaction with the intervention and its effect on the procedure.
Time frame: Reported immediately after the sequence a week later on day 2 (T4)
Plan to share: No
Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 32 months is above that.
Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.